Welcome to our dedicated page for ADMS news (Ticker: ADMS), a resource for investors and traders seeking the latest updates and insights on ADMS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ADMS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ADMS's position in the market.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced the presentation of two posters at the American Academy of Neurology's 73rd Annual Meeting. One poster focuses on GOCOVRI® (amantadine), the first FDA-approved treatment for dyskinesia in Parkinson's patients on levodopa therapy, addressing both dyskinesia and OFF episodes. The second poster presents survey results on the impact of dyskinesia in Parkinson's disease. The presentations highlight GOCOVRI's unique clinical profile and will be available for viewing from April 17 - 22, 2021.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. The live webcast is scheduled for April 14 at 3:00 PM Eastern Time and will be accessible on the company's investor relations website. A replay will be available for 30 days following the event. Adamas focuses on developing innovative medicines targeting neurological diseases, aimed at improving patient and caregiver quality of life.
Adamas Pharmaceuticals (Nasdaq: ADMS) announced a publication detailing the efficacy of GOCOVRI® (amantadine) for Parkinson's disease. The article in Frontiers in Neurology highlights that GOCOVRI significantly increased daily ON time without dyskinesia from 3.9 hours at baseline to 8.4 hours at Week 12 in a study of 196 patients. Compared to placebo, patients on GOCOVRI experienced an additional 2.9 hours of ON time. The results affirm GOCOVRI's unique position in addressing motor complications in Parkinson's disease.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) has granted restricted stock units to two new employees, allowing them to acquire a total of 57,000 shares of common stock. These units will vest over three years and were issued under the 2016 Inducement Plan approved by the board in March 2016. This initiative aims to attract talent to the company, which is dedicated to innovating therapies for neurological diseases.
Adamas Pharmaceuticals (Nasdaq: ADMS) has successfully closed its underwritten public offering of 12,500,000 shares of common stock, augmented by the underwriters' option for an additional 1,875,000 shares, priced at $4.40 each. The estimated net proceeds from this offering are anticipated to be $59.2 million after costs. SVB Leerink and William Blair served as joint bookrunning managers, with JMP Securities acting as lead manager. The offering was conducted under a shelf registration previously filed with the SEC, ensuring compliance and transparency.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) has priced its underwritten public offering of 12,500,000 shares of common stock at $4.40 per share. The offering is projected to raise gross proceeds of $55.0 million, excluding underwriters' commissions. Adamas has also granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares. The offering is expected to close on March 1, 2021. The shares are being offered under a shelf registration statement filed with the SEC, and details can be found in the prospectus available on the SEC's website.
Adamas Pharmaceuticals (Nasdaq: ADMS) has launched an underwritten public offering of its common stock, exclusively offering shares from the company. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. This move is subject to market conditions, with no guarantees on the offering's completion, size, or terms. SVB Leerink and William Blair serve as joint bookrunning managers, with JMP Securities as the lead manager. Shares are offered under a previously filed shelf registration statement with the SEC.
Adamas Pharmaceuticals (Nasdaq: ADMS) reported a 29% revenue increase to $21.0 million for Q4 2020, with GOCOVRI sales reaching $19.8 million, up 21% year-over-year. The company successfully launched GOCOVRI's second indication, now approved for 400,000 to 500,000 Parkinson’s patients. Net loss narrowed to $18.3 million from $23.1 million in Q4 2019. Full year revenue for 2020 was $74.5 million, with GOCOVRI product sales rising 30% from 2019. Adamas anticipates 2021 operating expenses of $115 million to $130 million.
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will present at several upcoming investor conferences. These include the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 1:40 p.m. ET, the Cowen 41st Annual Healthcare Conference on March 2 at 2:50 p.m. ET, and the H.C. Wainwright Global Life Sciences Conference with a prerecorded presentation available starting March 9 at 7:30 a.m. ET. Webcasts can be accessed for 30 days via the company's investor relations website.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) will report its fourth quarter and year-end 2020 financial results on February 23, 2021, after market close. Following the announcement, a conference call and webcast will take place at 4:30 p.m. Eastern Time to discuss the results and provide corporate updates. Investors can join the call by dialing specific numbers or access the live webcast via the company’s investor page, with a replay available for 30 days. Adamas aims to deliver innovative medicines addressing neurological diseases.
